TMEM182

Summary

TMEM182 (transmembrane protein 182, HGNC:26391) is a protein-coding gene on chromosome 2q12.1, encoding Transmembrane protein 182 (Q6ZP80). Negatively regulates myogenesis and skeletal muscle regeneration via its association with ITGB1.

Predicted to be involved in myotube cell development involved in skeletal muscle regeneration; negative regulation of myoblast differentiation; and negative regulation of myoblast fusion. Predicted to be located in plasma membrane.

Source: NCBI Gene 130827 — RefSeq curated summary.

At a glance

• GWAS associations: 29
• Clinical variants (ClinVar): 34 total
• MANE Select transcript: NM_144632

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26391
Approved symbol	TMEM182
Name	transmembrane protein 182
Location	2q12.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ30294
Ensembl gene	ENSG00000170417
Ensembl biotype	protein_coding
Entrez	130827

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000409173, ENST00000409528, ENST00000412401, ENST00000453878, ENST00000454536, ENST00000469971, ENST00000484094, ENST00000486293, ENST00000488134, ENST00000639249, ENST00000640575

RefSeq mRNA: 5 — MANE Select: NM_144632 NM_001321343, NM_001321344, NM_001321345, NM_001321346, NM_144632

CCDS: CCDS2064, CCDS82489, CCDS82490, CCDS92825

Canonical transcript exons

ENST00000412401 — 5 exons

Exon	Start	End
ENSE00001699684	102814748	102817679
ENSE00001956914	102762031	102762349
ENSE00003461545	102764329	102764427
ENSE00003514093	102762587	102762686
ENSE00003596027	102797863	102798000

Expression profiles

Bgee: expression breadth ubiquitous, 205 present calls, max score 99.45.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.0642 / max 233.6971, expressed in 1370 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
21771	3.0268	1341
21774	0.4966	64
21772	0.2818	43
21773	0.2590	50

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cardiac muscle of right atrium	UBERON:0003379	99.45	gold quality
left ventricle myocardium	UBERON:0006566	99.31	gold quality
myocardium	UBERON:0002349	98.46	gold quality
vastus lateralis	UBERON:0001379	98.33	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.24	gold quality
heart right ventricle	UBERON:0002080	98.00	gold quality
quadriceps femoris	UBERON:0001377	97.82	gold quality
biceps brachii	UBERON:0001507	97.67	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	97.05	gold quality
skeletal muscle tissue	UBERON:0001134	95.56	gold quality
deltoid	UBERON:0001476	95.38	gold quality
cardiac atrium	UBERON:0002081	94.83	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.83	gold quality
right atrium auricular region	UBERON:0006631	94.54	gold quality
body of tongue	UBERON:0011876	94.21	gold quality
cardiac ventricle	UBERON:0002082	93.66	gold quality
heart left ventricle	UBERON:0002084	93.60	gold quality
muscle tissue	UBERON:0002385	93.26	gold quality
tibialis anterior	UBERON:0001385	91.84	silver quality
heart	UBERON:0000948	90.92	gold quality
apex of heart	UBERON:0002098	90.42	gold quality
muscle of leg	UBERON:0001383	89.46	gold quality
gastrocnemius	UBERON:0001388	89.15	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.25	gold quality
vena cava	UBERON:0004087	87.58	gold quality
tongue	UBERON:0001723	85.19	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.83	gold quality
islet of Langerhans	UBERON:0000006	77.73	gold quality
ventricular zone	UBERON:0003053	77.03	gold quality
superior surface of tongue	UBERON:0007371	76.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.78

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

89 targeting TMEM182, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3163	100.00	77.23	8605
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-576-5P	99.84	70.46	2582

Literature-anchored findings (GeneRIF, showing 2)

• Tumor necrosis factor alpha (TNF-alpha)-mediated expression of TMEM182 was regulated by miR-450a induction in oral squamous cell carcinoma. MiR-450a-reduced cellular adhesion was abolished by TMEM182 restoration. (PMID:30893332)
• Identification of a TMEM182 rs141764639 polymorphism associated with central obesity by regulating tumor necrosis factor-alpha in a Korean population. (PMID:32938560)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem182a	ENSDARG00000040374
danio_rerio	tmem182b	ENSDARG00000087285
mus_musculus	Tmem182	ENSMUSG00000079588
rattus_norvegicus	Tmem182	ENSRNOG00000028945

Protein

Protein identifiers

Transmembrane protein 182 — Q6ZP80 (reviewed: Q6ZP80)

All UniProt accessions (7): Q6ZP80, A0A1W2PQA2, A0A1W2PS41, A0A494C0U9, A0A494C149, B8ZZ71, C9IYX5

UniProt curated annotations — full annotation on UniProt →

Function. Negatively regulates myogenesis and skeletal muscle regeneration via its association with ITGB1. Modulates ITGB1 activation by decreasing ITGB1-LAMB1 interaction and inhibiting ITGB1-mediated intracellular signaling during myogenesis.

Subunit / interactions. Interacts with ITGB1.

Subcellular location. Cell membrane.

Similarity. Belongs to the TMEM182 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6ZP80-1	1	yes
Q6ZP80-2	2
Q6ZP80-3	3

RefSeq proteins (5): NP_001308272, NP_001308273, NP_001308274, NP_001308275, NP_653233* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004031	PMP22/EMP/MP20/Claudin	Family
IPR026763	TMEM182	Family

Pfam: PF13903

UniProt features (15 total): topological domain 4, transmembrane region 3, glycosylation site 2, splice variant 2, signal peptide 1, chain 1, sequence variant 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6ZP80-F1	87.24	0.52

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 47, 102

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 112 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, GOBP_SKELETAL_MUSCLE_TISSUE_REGENERATION, NKX25_02, chr2q12, GOBP_GROWTH, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_REGENERATION, AP4_Q6, TGACCTY_ERR1_Q2, MEF2_02, AAAYRNCTG_UNKNOWN, CAGCTG_AP4_Q5, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_REGULATION_OF_MYOBLAST_DIFFERENTIATION, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT

GO Biological Process (5): muscle organ development (GO:0007517), myotube cell development involved in skeletal muscle regeneration (GO:0014906), myotube differentiation involved in skeletal muscle regeneration (GO:0014908), negative regulation of myoblast differentiation (GO:0045662), negative regulation of myoblast fusion (GO:1901740)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
skeletal muscle tissue regeneration	2
animal organ development	1
muscle structure development	1
myotube cell development	1
myotube differentiation involved in skeletal muscle regeneration	1
myotube differentiation	1
myoblast differentiation	1
negative regulation of cell differentiation	1
regulation of myoblast differentiation	1
myoblast fusion	1
negative regulation of syncytium formation by plasma membrane fusion	1
regulation of myoblast fusion	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

578 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM182	SLC67A2	Q8NBP5	666
TMEM182	TM6SF1	Q9BZW5	499
TMEM182	MCTP2	Q6DN12	472
TMEM182	PLCH2	O75038	448
TMEM182	SHISAL2B	A6NKW6	441
TMEM182	VWC2L	B2RUY7	438
TMEM182	TAFA1	Q7Z5A9	420
TMEM182	TTC36	A6NLP5	397
TMEM182	MYMK	A6NI61	396
TMEM182	CDH15	P55291	390
TMEM182	CADM2	Q8N3J6	381
TMEM182	LAMP5	Q9UJQ1	377
TMEM182	ADGRF2P	Q8IZF7	375
TMEM182	ZNF738	Q8NE65	371
TMEM182	TSPAN33	Q86UF1	362

IntAct

51 interactions, top by confidence:

A	B	Type	Score
SYNE4	TMEM182	psi-mi:“MI:0915”(physical association)	0.560
TMEM182	SYNE4	psi-mi:“MI:0915”(physical association)	0.560
TMEM182	LGALS3	psi-mi:“MI:0915”(physical association)	0.560
TMEM182	CLDN5	psi-mi:“MI:0915”(physical association)	0.560
KLRC1	TMEM182	psi-mi:“MI:0915”(physical association)	0.560
TMEM182	MS4A3	psi-mi:“MI:0915”(physical association)	0.560
TMEM182	SMIM3	psi-mi:“MI:0915”(physical association)	0.560
	TMEM182	psi-mi:“MI:0915”(physical association)	0.560
GPR42	TMEM182	psi-mi:“MI:0915”(physical association)	0.560
TMEM182	TMEM140	psi-mi:“MI:0915”(physical association)	0.560
PLP1	TMEM182	psi-mi:“MI:0915”(physical association)	0.560
TMEM182	SUSD3	psi-mi:“MI:0915”(physical association)	0.560
GJA8	TMEM182	psi-mi:“MI:0915”(physical association)	0.560
TSPAN12	TMEM182	psi-mi:“MI:0915”(physical association)	0.560
TMEM182	FNDC9	psi-mi:“MI:0915”(physical association)	0.560
TMEM218	TMEM182	psi-mi:“MI:0915”(physical association)	0.560
CLDN5	TMEM182	psi-mi:“MI:0915”(physical association)	0.560
MALL	TMEM182	psi-mi:“MI:0915”(physical association)	0.560
TMEM182	LGALS3	psi-mi:“MI:0914”(association)	0.560
TMEM182	SRPRA	psi-mi:“MI:0914”(association)	0.350
TMEM182	KLRC1	psi-mi:“MI:0915”(physical association)	0.000
TMEM182	MS4A3	psi-mi:“MI:0915”(physical association)	0.000
TMEM182	SMIM3	psi-mi:“MI:0915”(physical association)	0.000
TMEM182		psi-mi:“MI:0915”(physical association)	0.000
TMEM140	TMEM182	psi-mi:“MI:0915”(physical association)	0.000
TMEM182	PLP1	psi-mi:“MI:0915”(physical association)	0.000
TMEM182	SUSD3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (23): SYNE4 (Two-hybrid), LGALS3 (Affinity Capture-MS), TMEM182 (Two-hybrid), TMEM182 (Two-hybrid), TMEM182 (Two-hybrid), TMEM182 (Two-hybrid), TMEM182 (Two-hybrid), TMEM182 (Two-hybrid), TMEM182 (Two-hybrid), TMEM182 (Two-hybrid), TMEM182 (Two-hybrid), TMEM182 (Two-hybrid), FNDC9 (Two-hybrid), TMEM31 (Two-hybrid), CLDN5 (Two-hybrid)

ESM2 similar proteins: A0A1D5NY17, A4IF75, B2RVY9, B3SHH9, F6V1J6, O42281, O70578, P19518, P97707, Q06432, Q08CE6, Q08DE1, Q0D289, Q0V9E0, Q14714, Q2MJQ7, Q4R4Z3, Q4V922, Q5CZV0, Q5PRC1, Q5RDV7, Q5XGU1, Q62147, Q66IV3, Q68FV0, Q6AZD1, Q6P0C6, Q6R5J2, Q6ZP80, Q6ZUX7, Q7ZZL8, Q86WI0, Q8BGA2, Q8NBL3, Q8VHW3, Q8VHW4, Q8VHW7, Q8VHW8, Q91Y55, Q925N4

Diamond homologs: A0A1D5NY17, A4IF75, B2RVY9, Q0V9E0, Q5CZV0, Q6ZP80

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

34 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	25
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

777 predictions. Top by Δscore:

Variant	Effect	Δscore
2:102762673:G:GT	donor_gain	1.0000
2:102762682:GTACA:G	donor_gain	1.0000
2:102762683:TACA:T	donor_gain	1.0000
2:102762684:ACA:A	donor_gain	1.0000
2:102762686:AGT:A	donor_loss	1.0000
2:102762687:G:GG	donor_gain	1.0000
2:102762687:GTA:G	donor_loss	1.0000
2:102762688:T:G	donor_loss	1.0000
2:102764317:T:A	acceptor_gain	1.0000
2:102764325:CTA:C	acceptor_loss	1.0000
2:102764327:A:AG	acceptor_gain	1.0000
2:102764327:A:T	acceptor_loss	1.0000
2:102764328:G:GA	acceptor_gain	1.0000
2:102764328:GC:G	acceptor_gain	1.0000
2:102764328:GCC:G	acceptor_gain	1.0000
2:102764328:GCCA:G	acceptor_gain	1.0000
2:102764328:GCCAA:G	acceptor_gain	1.0000
2:102764424:G:GG	donor_gain	1.0000
2:102764424:GTTA:G	donor_loss	1.0000
2:102764425:TTA:T	donor_gain	1.0000
2:102764425:TTAG:T	donor_loss	1.0000
2:102764426:TA:T	donor_gain	1.0000
2:102764426:TAG:T	donor_loss	1.0000
2:102764427:AGT:A	donor_loss	1.0000
2:102764428:G:GG	donor_gain	1.0000
2:102764428:GTA:G	donor_loss	1.0000
2:102764429:TAA:T	donor_loss	1.0000
2:102764430:AAGT:A	donor_loss	1.0000
2:102797851:T:A	acceptor_gain	1.0000
2:102797852:G:A	acceptor_gain	1.0000

AlphaMissense

1500 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:102797922:A:C	S131R	0.997
2:102797924:C:A	S131R	0.997
2:102797924:C:G	S131R	0.997
2:102762629:T:A	C59S	0.995
2:102762630:G:C	C59S	0.995
2:102762614:G:A	G54R	0.994
2:102762614:G:C	G54R	0.994
2:102764352:T:A	C86S	0.994
2:102764353:G:C	C86S	0.994
2:102762614:G:T	G54W	0.993
2:102762629:T:C	C59R	0.993
2:102762305:T:A	W30R	0.992
2:102762305:T:C	W30R	0.992
2:102762615:G:A	G54E	0.991
2:102762631:T:G	C59W	0.991
2:102764352:T:C	C86R	0.991
2:102764354:C:G	C86W	0.991
2:102762266:G:A	G17R	0.990
2:102762266:G:C	G17R	0.990
2:102762309:T:C	L31P	0.990
2:102762630:G:A	C59Y	0.990
2:102764353:G:A	C86Y	0.990
2:102797869:G:C	R113P	0.990
2:102797877:T:A	W116R	0.990
2:102797877:T:C	W116R	0.990
2:102762630:G:T	C59F	0.988
2:102762608:C:G	H52D	0.987
2:102762307:G:C	W30C	0.986
2:102762307:G:T	W30C	0.986
2:102762246:G:A	G10E	0.985

dbSNP variants (sampled 300 via entrez): RS1000088219 (2:102840635 G>C,T), RS1000118395 (2:102844124 G>A), RS1000180796 (2:102765578 A>G), RS1000194982 (2:102760963 T>C,G), RS1000236733 (2:102814261 C>T), RS1000240497 (2:102772571 G>A), RS1000243776 (2:102807323 T>C), RS1000256177 (2:102767294 A>T), RS1000291668 (2:102795447 A>G), RS1000322408 (2:102795213 T>G), RS1000336312 (2:102755027 T>G), RS1000341571 (2:102789311 A>G), RS1000349515 (2:102830839 A>C), RS1000393170 (2:102820382 A>G), RS1000443294 (2:102844045 C>A,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

29 associations (top):

Study	Trait	p-value
GCST002471_2	Blood pressure (anthropometric measures interaction)	5.000000e-08
GCST002929_9	Chromium levels	5.000000e-06
GCST003542_105	Night sleep phenotypes	9.000000e-06
GCST003992_24	Photic sneeze reflex	3.000000e-08
GCST004705_2	Blood pressure	4.000000e-08
GCST007045_17	PR interval	3.000000e-15
GCST007323_88	Risk-taking tendency (4-domain principal component model)	8.000000e-10
GCST007325_123	General risk tolerance (MTAG)	3.000000e-11
GCST007326_79	Number of sexual partners	4.000000e-08
GCST007327_170	Smoking status (ever vs never smokers)	2.000000e-10
GCST007327_207	Smoking status (ever vs never smokers)	1.000000e-21
GCST007335_5	Age at first sexual intercourse	3.000000e-08
GCST007603_29	Smoking initiation	9.000000e-14
GCST008810_58	Smoking initiation (ever regular vs never regular)	6.000000e-16
GCST010321_106	PR interval	4.000000e-34
GCST010796_4531	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-10
GCST010796_4532	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-10
GCST010796_4533	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-11
GCST010796_4534	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-11
GCST010796_4535	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-11
GCST010796_4536	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-10
GCST010796_4537	Electrocardiogram morphology (amplitude at temporal datapoints)	7.000000e-10
GCST010796_4538	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-11
GCST010988_185	Adult body size	1.000000e-09
GCST011534_4	Sun-seeking behavior	2.000000e-08
GCST011703_51	Smoking initiation	1.000000e-15
GCST011704_5	Smoking status (current vs never)	5.000000e-08
GCST012381_4	Eosinophilic esophagitis	4.000000e-10
GCST90027899_2	Eosinophilic esophagitis	4.000000e-10

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0006335	systolic blood pressure
EFO:0007887	autosomal dominant compelling helio-ophthalmic outburst syndrome
EFO:0006336	diastolic blood pressure
EFO:0004462	PR interval
EFO:0008579	risk-taking behaviour
EFO:0004318	smoking behavior
EFO:0009749	age at first sexual intercourse measurement
EFO:0005670	smoking initiation
EFO:0004327	electrocardiography
EFO:0010729	sun exposure measurement
EFO:0006527	smoking status measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	increases expression	3
entinostat	affects cotreatment, decreases expression	2
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases methylation	1
sodium arsenite	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
incobotulinumtoxinA	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Air Pollutants	increases abundance, increases expression	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Methyl Methanesulfonate	increases expression	1
Valproic Acid	affects expression	1
Asbestos, Crocidolite	decreases methylation	1
Cadmium Chloride	decreases expression	1
Particulate Matter	increases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.